Navigation Links
BRCA Mutations Don't Raise Breast Cancer Risk Equally
Date:1/8/2008

Study finds wide variation among families with carriers

TUESDAY, Jan. 8 (HealthDay News) -- Not all carriers of the BRCA1 and BRCA2 genetic mutations show the same risk for developing breast cancer.

In fact, a new study finds wide variation in risk among families carrying the mutations, indicating that the mutations are influenced by other genetic, and possibly environmental, factors.

"Risk among carriers varies considerably, and, if you accept that that's the case, there must be a reason why it varies, and the most plausible explanation is that there are other genetic factors affecting breast cancer risk that are being passed on through these families," said study author Colin Begg, chairman of the department of epidemiology and biostatistics at Memorial Sloan-Kettering Cancer Center in New York City.

And that's where more work needs to be done, said Begg, whose report was published in the Jan. 9/16 issue of the Journal of the American Medical Association.

"They're saying that not all BRCA mutations are created equal," added Dr. Len Lichtenfeld, deputy chief medical officer at the American Cancer Society.

It is known that the BRCA1 and BRCA2 gene mutations raise a woman's risk for developing breast cancer, so the degree of that risk is critical in helping a woman make choices about prevention.

But most previous studies have only looked at overall risk among mutation carriers, not individual risk or risk in specific groups.

"To some extent, people have traditionally perceived the risk as being a fixed thing," Begg said. "People have studied BRCA1 and 2 separately, but, other than that, there's the sense that if you're a carrier, you have a certain risk, and it's a high risk, and that's it."

Experts have hypothesized that there is variation in the risk of breast cancer in general due to other, as yet unknown, genetic factors, but there's scant evidence of such a variation. There has been no research on whether such variation exists among BRCA mutation carriers.

This study provides such evidence.

Begg and his colleagues genotyped more than 2,000 participants in the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study who had been diagnosed with breast cancer. Of the total, 1,394 women had unilateral breast cancer (one breast only), while 704 had contralateral breast cancer (an additional malignancy in the opposite breast).

This study focused on the 181 women who were shown to be mutation carriers.

First-degree relatives of BRCA1 and 2 carriers had a higher risk of developing breast cancer if their proband (the relative whose breast cancer diagnosis first brought the family history to light) was diagnosed at a younger age (35 or under). The overall study only looked at women who had been diagnosed under the age of 55.

There was also a non-statistically significant trend toward higher risk for first-degree relatives of women with contralateral breast cancer as opposed to unilateral breast cancer.

The results strongly indicate that factors other than the BRCA mutations influence risk.

"If everyone with a mutation has exactly the same risk, then the presence of the mutation is the only factor that influences risk in carriers, [and] there are no other factors that can influence risk," Begg explained. "The fact that we see that age at diagnosis in the proband influences risk in the relatives implies that there is something else about the carrier families with a "young" proband that must influence risk. The presumption is that these families are passing on other genetic characteristics that positively influence breast cancer risk."

Although the authors state there is no need for wide screening of women yet, future technological advances may make such screening feasible.

"Lots of research is being done on the whole genome to identify new risk factors for breast cancer, and there's a certain amount of debate as to whether this is a worthwhile exercise or not. There's only a point to searching if something is to be found there," Begg explained. "This kind of study suggests that there is something to be found, and that it is worthwhile doing these studies not just on mutation carriers but on people with breast cancer on the whole. Our premise is that the additional breast cancer risk factors that will be found will be applicable to carriers just like to anyone else."

"This is a very, very interesting article, and very important. These two genes represent about 7 percent of all breast cancers and usually account for breast cancer in families and in young women," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "We're understanding more about how patients can accept the risk that has been assigned to them. This is a very important paper going forward."

More information

There's an overview of the genetics of breast cancer at the U.S. National Cancer Institute.



SOURCES: Colin Begg, Ph.D., chairman, department of epidemiology and biostatistics, Memorial Sloan-Kettering Cancer Center, New York City; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; Jan. 9/16, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Ashkenazi ovarian cancer patients with BRCA mutations live longer than those with normal gene
2. Gene Mutations May Cause Rare Neonatal Diabetes
3. Survey confirms Americans prefer root canal treatment by endodontists
4. Ortho Organizers(R) Announces the Launch of the Ancor Pro(TM) Orthodontic Anchorage System Hands-on Course
5. Treating your periodontal pockets may benefit your pocket book
6. Growing Link Between Diabetes and Periodontal Disease Focus of National Gathering for Health Care Leaders
7. Anxiety Raises Heart Attack Risk
8. High Levels of Stress After 9/11 Raised Heart Disease Risk
9. Lack of Deep Sleep Raises Diabetes Risk
10. High triglycerides, other cholesterol raise risk of stroke
11. Temporary Amnesia, Confusion Raise Stroke, Dementia Risk
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BRCA Mutations Don't Raise Breast Cancer Risk Equally
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: